Antihypertensive Medications and Anemia
Authors:
Open Access
- 5 September 2007
- journal article
- review article
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 9 (9) , 723-727
Abstract
Antihypertensive medication use can be associated with a reduction in hemoglobin concentration. The magnitude of such a change is generally small, but in certain instances it can be extreme enough to produce a clinically significant degree of anemia. The mechanistic basis for antihypertensive medication‐related changes in hemoglobin concentration include hemodilution, hemolytic anemia, and suppression of red blood cell production, as this occurs most commonly with angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers. A reduction in hemoglobin concentration in a patient who is receiving treatment for hypertension and does not have an obvious source of blood loss should account for potential antihypertensive therapy involvement.Keywords
This publication has 49 references indexed in Scilit:
- Intravenous Iron Alone for the Treatment of Anemia in Patients With Chronic Heart FailureJACC, 2006
- Prevalence and Prognostic Significance of Anemia in Patients With Congestive Heart Failure Treated With Standard vs High Doses of EnalaprilThe Journal of Heart and Lung Transplantation, 2006
- Levels of Hematopoiesis Inhibitor N -Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart FailureCirculation, 2005
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trialThe Lancet, 2002
- Negative Effect of Angiotensin-Converting Enzyme Inhibitors on Erythropoietin Response in CAPD PatientsAmerican Journal of Nephrology, 2000
- Renal and Metabolic Clearance ofN-Acetyl-Seryl-Aspartyl-Lysyl-Proline (AcSDKP) During Angiotensin-Converting Enzyme Inhibition in HumansHypertension, 1999
- Angiotensin Converting Enzyme Inhibitors Are Associated with the Need for Increased Recombinant Human Erythropoietin Maintenance Doses in Hemodialysis PatientsNephron, 1997
- Nimodipine Neuroprotection in Cardiac Valve ReplacementStroke, 1996
- Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profilesThe American Journal of Cardiology, 1994